In our study, IDHm, 1p19q codeletion (or ATRX protein expression), percentage of Ki67-positive cells and histological grade were associated with survival of patients with recurrent grades II–III glioma from diagnosis, but not from bevacizumab initiation. Here, ATRX is linked to central nervous system cancer.